Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERO: Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer
NCT05705401Phase 3Active, not recruiting
- Sponsor
- NRG Oncology
- Start
- May 2023
- Primary completion
- Feb 2034
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in breast cancer (2 arms), sponsored by NRG Oncology. Primary endpoint: Recurrence-Free Interval at 10.5 years. Started May 2023; status: active, not recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05705401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05705401.